tiprankstipranks
Blurbs

H.C. Wainwright Initiates a Buy Rating on Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals (TARSResearch Report) received a Buy rating and a $40.00 price target from H.C. Wainwright analyst Oren Livnat today. The company’s shares closed last Monday at $24.13, close to its 52-week low of $21.00.

According to TipRanks.com, Livnat is a 2-star analyst with an average return of 1.0% and a 41.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Zynerba Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tarsus Pharmaceuticals with a $57.00 average price target.

See the top stocks recommended by analysts >>

Based on Tarsus Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.24 million and GAAP net loss of $15.7 million. In comparison, last year the company had a GAAP net loss of $10.14 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company’s lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.

Read More on TARS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed